Tag Archives: Mycophenolate

CellCept: 250 mg Capsules, 500 mg Tablets. Myfortic: 180, 360 mg Tablets

Mycophenolate Mofetil (mye-koe-fee-noe-late moe-fe-til) [CellCept] Mycophenolic Acid (mye-koe-fee-noe-lik) [Myfortic] Drug Classification (The therapeutic classification, which categorizes drugs by the disease state they are used to treat, appears first, followed by the pharmacologic classification, which is based on the drug’s mechanism of action.) Therapeutic class: immunosuppressants Pregnancy Category (pregnancy categories (A, B, C, D, and X)… Read More »

Other Off-Label Agents Used in the Treatment of RRMS

Corticosteroids Corticosteroids are considered as standard treatment for acute relapses. Corticosteroids decrease inflammation and stabilize the blood brain barrier, resulting in more rapid recovery from relapses. The standard dose is 1 g of methylprednisolone (MP) daily for 3-5 days through I/V infusion, although other regimens also have been used. Some studies have suggested that oral… Read More »

Treatment of the epilepsy patient with renal disease

Seizures may occur in uraemic encephalopathy, dialysis disequilibrium syndrome and dialysis encephalopathy. In addition, renal insufficiency and dialysis may both have effects on anti-epileptic drug pharmacokinetics. Renal impairment can alter the fraction of anti-epileptic drug absorbed, volume of distribution, protein binding and renal drug clearance. Renal impairment may alter the gastric pH, cause small intestinal… Read More »

Treatment Of Breakthrough Disease

There is consensus that therapy in relapsing-remitting multiple sclerosis (MS) in the pediatric age group should be initiated with first-line treatments approved for adult multiple sclerosis (MS), namely one of the three forms of interferon-beta or glatiramer acetate (GA). However, as in adults with multiple sclerosis (MS), the disease remains clinically or radiologically active in… Read More »

Breakthrough Therapies: Drugs Approved in Other Indications

Cyclophosphamide Cyclophosphamide is an alkylating agent that is used to treat various types of cancer as well as autoimmune diseases. The main effect of cyclophosphamide is attributed to its metabolite phosphoramide mustard, which forms DNA interstrand crosslinks in cells with low levels of aldehyde dehydrogenase, leading to cell death. For multiple sclerosis therapy, cyclophosphamide is… Read More »

Breakthrough Therapies: Monoclonal antibodies

Rituximab Rituximab is a chimerk monoclonal antibody specific for the B-lymphocyte surface protein CD20. Rituximab induces a very rapid and dramatic depletion of B cells via mechanisms including apoptosis and immune-mediated cytotoxkity. Plasma cells lack CD20 and are therefore not affected by rituximab. B cells are replenished from pre-B cells coming from the bone marrow… Read More »